Skip to content

DR. JASMINE ROORYCK

Active
Private limited companyfounded 2021active for 5 yearsArdooisesteenweg 408, 8800 Roeselare, BelgiumKBO/BCE: BE 0765.568.738
Summary

DR. JASMINE ROORYCK has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €168,000 and a net result of €167,000. Equity has been growing by about 5.2% per year since 2021. Its solvency ranks better than 53% of 3,032 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Overview

Official details

Source: KBO
Status
Active since 23-03-2021 Normal situation
Activity
General medical practice NACE 86210and 1 other
Establishment unit
2.315.445.923 8700 Tielt, since 23-03-2021
Financial year end
30 September
Peppol
Reachable since 21-11-2024

Board and ownership

Board
  • Rooryck JasmineDirector

Financial position

96 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Annual accounts to 30-09-2025
Gross margin
€234,166
▲ 50.2%
Turnover
≈ €430,000
estimated
Profit
€167,000
▲ 30.4%
Equity
€168,000
▲ 25.3%
Total assets
€271,488
▲ 81.8%
Score breakdownlowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 1.25, cash €124,740Size: total assets €271,488Equity €168,000 (61.9% of total assets)Show the evidence

Checked score

Score 2025
96 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 66% of micro companies in human health (NACE 86)
Financial strength · tick: 2024
Strong
Solvency 87-13
equity 61.9% of total assets
Liquidity 83+21
short-term debt 37.1% · cash 45.9%
Profitability 100=
return on assets 61.5%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,160 companies, NACE 86, micro)
Last 24 months 12-2024: < 0.1%lowest value 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: 0.1%▲ +0.1 percentage points vs 04-2025 06-2025: 0.1%● unchanged vs 05-2025 07-2025: 0.1%● unchanged vs 06-2025 08-2025: 0.1%● unchanged vs 07-2025 09-2025: 0.1%● unchanged vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026highest value 05-2026: < 0.1%▼ -0.1 percentage points vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026 11-2026: < 0.1%● unchanged vs 10-2026
Credit of up to €16,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.25 (1.77 in 2024), below the usual 1.5. Short-term debt is 37.1% and cash 45.9% of total assets. 38.1% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 50% of them on solvency, 66% on liquidity, 80% on profitability and 69% on growth.

The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskneutral
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Liquidity: current ratio 1.25, cash €124,740
NBB · annual accounts
lowers risk · Size: total assets €271,488
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
lowers risk · Equity €168,000 (61.9% of total assets)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 30-03-2026, 31 days ahead of the deadline.
NBB · 5 filings
Deviation from the deadline
2025
31 days early
2024
15 days early
2023
26 days early
2022
31 days early
2021
10 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 5 accounts on average 23 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-09-2026 is due by 30-04-2027. Nothing is late today. The company usually files around 5 April (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
30-09-2026 year end02-11-2026 today30-04-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Key points

  • Positive: Always filed on timeaccounts within the deadline every year 5 years View
  • Positive: 5 profitable years in a rowprofit 2025: €167,000 5 years View

Recent changes

  1. · Gazette deed Capital contribution · Other provision
  2. · Gazette deed Founder · Incorporation
  3. · Gazette deed Incorporation
All 11 events

Comparable companies

These companies have the same main activity as DR. JASMINE ROORYCK: general medical practice (NACE 86210). They are comparable in size and age: total assets between €232,000 and €305,000, founded between 2020 and 2021.

CompanyTotal assetsGross margin
DR. JASMINE ROORYCK Roeselare€271,488€234,166
Thijs Vandewalle Poperinge€272,966€228,273
Artsenpraktijk Axel Decraene Ingelmunster€305,116€223,909
DR. NELE BOLLEN Izegem€232,430€221,604
Dr. Kevin Raemdonck Niel€270,316€240,407
Dr. Nino Van der Loo Lommel€253,132€232,524
DOKTER ZHANG LI Grimbergen€252,079€237,117
Full comparison

Key facts about DR. JASMINE ROORYCK

What is the company number of DR. JASMINE ROORYCK?
The company number of DR. JASMINE ROORYCK is 0765.568.738. The VAT number is the same number with BE in front: BE 0765.568.738.
Where is DR. JASMINE ROORYCK based?
The registered office is at Ardooisesteenweg 408, 8800 Roeselare.Company details
What does DR. JASMINE ROORYCK do?
According to the KBO register, the main activity is general medical practice (NACE 86210).
What is the legal form of DR. JASMINE ROORYCK?
The legal form of DR. JASMINE ROORYCK is Private limited company (BV).
When was DR. JASMINE ROORYCK founded?
DR. JASMINE ROORYCK was founded on 23-03-2021.
Is DR. JASMINE ROORYCK still active?
Yes, DR. JASMINE ROORYCK is an active enterprise in the KBO register.
What is the turnover of DR. JASMINE ROORYCK?
The turnover in financial year 2025 is ≈ €430,000. This figure is estimated from the gross margin of €234,166 and 30 comparable companies (NACE 86210). It probably lies between €340,000 and €530,000.Financials
Is DR. JASMINE ROORYCK profitable?
In financial year 2025, DR. JASMINE ROORYCK made a profit of €167,000.
Where can I find the annual accounts of DR. JASMINE ROORYCK?
DR. JASMINE ROORYCK filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DR. JASMINE ROORYCK due?
DR. JASMINE ROORYCK must file the annual accounts for financial year 2026 by 30-04-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.